JP2009525990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525990A5 JP2009525990A5 JP2008553588A JP2008553588A JP2009525990A5 JP 2009525990 A5 JP2009525990 A5 JP 2009525990A5 JP 2008553588 A JP2008553588 A JP 2008553588A JP 2008553588 A JP2008553588 A JP 2008553588A JP 2009525990 A5 JP2009525990 A5 JP 2009525990A5
- Authority
- JP
- Japan
- Prior art keywords
- blood lipid
- lipid concentration
- berberine
- composition
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 30
- 239000008280 blood Substances 0.000 claims 25
- 210000004369 blood Anatomy 0.000 claims 25
- 150000002632 lipids Chemical class 0.000 claims 25
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 14
- 229940093265 berberine Drugs 0.000 claims 14
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 14
- 241000196324 Embryophyta Species 0.000 claims 9
- 235000002378 plant sterols Nutrition 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000037396 body weight Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000004930 Fatty Liver Diseases 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims 2
- 235000008696 isoflavones Nutrition 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims 1
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- -1 omega-3 fatty acid ester Chemical class 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 229940026314 red yeast rice Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000037221 weight management Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71145506P | 2006-02-09 | 2006-02-09 | |
| PCT/CA2007/000194 WO2007090289A1 (en) | 2006-02-09 | 2007-02-09 | Combinations of botanical extracts for promoting cardiovascular health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525990A JP2009525990A (ja) | 2009-07-16 |
| JP2009525990A5 true JP2009525990A5 (enExample) | 2010-04-02 |
Family
ID=38344842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553588A Pending JP2009525990A (ja) | 2006-02-09 | 2007-02-09 | 医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8895079B2 (enExample) |
| EP (1) | EP1983989B1 (enExample) |
| JP (1) | JP2009525990A (enExample) |
| CA (1) | CA2640414C (enExample) |
| DK (1) | DK1983989T3 (enExample) |
| WO (1) | WO2007090289A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| US8716249B2 (en) * | 2008-01-31 | 2014-05-06 | Energy Light Llc | Compositions and methods for improving cardiovascular health |
| WO2009133458A1 (en) * | 2008-05-01 | 2009-11-05 | Afexa Life Sciences Inc. | Pharmaceutical composition comprising extracts of huanglian and ku ding cha effective for lowering blood lipid levels |
| TWI454221B (en) * | 2008-07-14 | 2014-10-01 | Composition and method for inhibiting formation of body fat | |
| ITMI20081403A1 (it) | 2008-07-29 | 2010-01-30 | Velleja Res Srl | Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico |
| TWI589228B (zh) * | 2009-04-23 | 2017-07-01 | S A Corman | 降低膽固醇含量之奶產品 |
| IT1405432B1 (it) * | 2010-12-16 | 2014-01-10 | Funcional Food Res S R L | Preparazione alimentare funzionale ed uso relativo. |
| WO2013016741A1 (en) * | 2011-07-22 | 2013-01-31 | Smith Conrad Anton | Dietary supplement for use in a weight loss program |
| US20150335615A1 (en) * | 2013-01-04 | 2015-11-26 | Toshihisa Kawai | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
| US9637731B2 (en) | 2013-03-05 | 2017-05-02 | Innovative Environmental Technologies, Inc. | Heavy metal stabilization and methane inhibition during induced or naturally occurring reducing conditions in contaminated media |
| US9221699B2 (en) * | 2013-03-05 | 2015-12-29 | Innovative Environment Technologies, Inc. | Inhibition of methane production during anaerobic reductive dechlorination |
| KR20250008786A (ko) * | 2014-07-29 | 2025-01-15 | 센젠 하이타이드 바이오파마슈티컬 리미티드 | 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법 |
| ITUB20150541A1 (it) | 2015-03-03 | 2016-09-03 | Acraf | Composizione comprendente sostanze e/o estratti naturali |
| CN106692973A (zh) * | 2015-11-13 | 2017-05-24 | 深圳君圣泰生物技术有限公司 | 一种组合物及其用途、药物制剂 |
| CA3023648C (en) * | 2016-05-10 | 2023-11-28 | Shenzhen Hightide Biopharmaceutical, Ltd. | Pharmaceutical composition of berberine with epa and dha |
| MX2019011678A (es) * | 2017-03-28 | 2020-02-12 | IRP Health Pty Ltd | Alcaloides de berberina en la prevencion y/o tratamiento de una enfermedad intestinal. |
| ES2645028B2 (es) * | 2017-10-13 | 2018-06-04 | Maria D. GÓMEZ GARRE | Preparación farmacéutica única y estable que contiene berberina, en formulación de liberación lenta, una estatina y ubiquinol para el tratamiento de la enfermedad cardiovascular y los factores de riesgo asociados |
| IT202300006831A1 (it) | 2023-04-06 | 2024-10-06 | Dompe Farm Spa | Composizione a base di estratti vegetali utile per il trattamento delle dislispidemie |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2524783B2 (ja) * | 1987-12-03 | 1996-08-14 | 科研製薬株式会社 | 家畜・家禽の肝機能改善剤 |
| US5589182A (en) | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
| JPH0995452A (ja) | 1995-07-21 | 1997-04-08 | Res Inst For Prod Dev | 脂肪分解促進剤 |
| JPH09255570A (ja) * | 1996-03-21 | 1997-09-30 | Fujitsuko Kk | 血中脂質濃度を低減させる薬剤及び可食性組成物 |
| KR20000021073A (ko) | 1998-09-25 | 2000-04-15 | 박원배 | 콜레스테롤 생합성 저해제 |
| KR100317112B1 (ko) | 1999-03-18 | 2001-12-22 | 한영복 | 지모와 황백피의 혼합 수추출물을 포함하는 염증 및 통증 치료용조성물 및 그 제조 방법 |
| US6998501B1 (en) * | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
| SE517769C2 (sv) * | 1999-10-29 | 2002-07-16 | Triple Crown Ab | Kolesterol och blodfettsänkande komposition, innehållande fytosteroler, blandade med monoglycerider |
| US6436406B1 (en) * | 2000-06-15 | 2002-08-20 | A. Glenn Braswell | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| CN1239155C (zh) * | 2003-01-23 | 2006-02-01 | 北京中医药大学 | 一种治疗缺血性脑中风的药物组合物及其制备方法 |
| JP2004331635A (ja) | 2003-05-04 | 2004-11-25 | Kaicho Se | 細胞遣伝情報正常化材料及びその製法 |
| CN1759834B (zh) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
-
2007
- 2007-02-09 JP JP2008553588A patent/JP2009525990A/ja active Pending
- 2007-02-09 US US12/223,297 patent/US8895079B2/en not_active Expired - Fee Related
- 2007-02-09 EP EP07710609.4A patent/EP1983989B1/en not_active Not-in-force
- 2007-02-09 WO PCT/CA2007/000194 patent/WO2007090289A1/en not_active Ceased
- 2007-02-09 DK DK07710609.4T patent/DK1983989T3/da active
- 2007-02-09 CA CA2640414A patent/CA2640414C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barter et al. | Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease | |
| Razani et al. | Insulin resistance and atherosclerosis | |
| Basu et al. | Anti-atherogenic effects of seabuckthorn (Hippophaea rhamnoides) seed oil | |
| Naidu et al. | Ameliorative potential of gingerol: Promising modulation of inflammatory factors and lipid marker enzymes expressions in HFD induced obesity in rats | |
| Jahagirdar et al. | A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice | |
| EP1983989B1 (en) | Combinations of botanical extracts for promoting cardiovascular health | |
| NZ597193A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| Feng et al. | The protective effect of coptisine on experimental atherosclerosis ApoE−/− mice is mediated by MAPK/NF-κB-dependent pathway | |
| JP2007525470A (ja) | ステロール及び／又はスタノール及びコレステロール生合成阻害剤を含む新規化合物及び組成物、並びに様々な疾患及び症状の治療又は防止へのそれらの使用 | |
| RS51449B (sr) | Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija | |
| JP2014208683A (ja) | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 | |
| RU2015120181A (ru) | Чресслизистая доставка токотриенола | |
| Birnbaum et al. | PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins | |
| WO2012175049A1 (zh) | 酰胺类化合物、其制备方法及应用 | |
| JP5490409B2 (ja) | スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤 | |
| Zhao et al. | Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits | |
| JP2014513125A (ja) | 糖尿病の治療用組成物および方法 | |
| Cheng et al. | RasGRF1 participates in the protective effect of tanshinone IIA on depressive like behaviors of a chronic unpredictable mild stress induced mouse model | |
| Raparti et al. | Selective thyroid hormone receptor modulators | |
| JP2009511635A (ja) | 哺乳動物における高脂血症に関連する障害を治療するための方法 | |
| WO2013169648A1 (en) | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug | |
| Sabri et al. | Statins: a potential therapeutic addition to treatment for aneurysmal subarachnoid hemorrhage? | |
| JP2006523672A5 (enExample) | ||
| CN111821308A (zh) | 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用 | |
| JP2010526152A5 (enExample) |